Why the study?
Does a combination of rotavirus virus-like particle vaccines and live-attenuated virus improve immunogenicity and protection against human rotavirus in a neonatal gnotobiotic pig model?
Does a combination of rotavirus virus-like particle vaccines and live-attenuated virus improve immunogenicity and protection against human rotavirus in a neonatal gnotobiotic pig model?
A combination of mucosal inductive sites and live-attenuated vaccine combined with VLP vaccines is the most effective regimen for rotavirus vaccination in a gnotobiotic pig model.
Supports combined mucosal rotavirus vaccination in pig models; leaves open human translation and efficacy trials.
The authors discuss here rotavirus-like particle vaccines as an alternative approach to oral live-attenuated rotavirus vaccine and their efficacy in a gnotobiotic pig model. Rotavirus virus-like particles (VLPs) were evaluated in different doses, and routes of administration, and combined with live-attenuated virus and adjuvants. A VLP vaccine composed of rotavirus VP2 and VP6 was immunogenic in gnotobiotic pigs when inoculated intranasally; however, this vaccine failed to confer protection. A combination of oral attenuated human rotavirus and intranasal 2/6VLP vaccines conferred immunogenicity, partial protection against a human rotavirus challenge and induced IFN-γ-producing T cells in the ileum of pigs with similar frequencies to human rotavirus infection. Vaccination through a combination of mucosal inductive sites and live-attenuated vaccine combined with VLP vaccines was the most effective regimen, compared with the use of a single route or a single vaccine alone. However, if formulated with neutralizing antigens, VLP vaccines may constitute a better approach in a high maternal antibody scenario.
No takes yet. Share an insight, caveat, or question.
Azevedo et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: